BIO-RAD LABORATORIES, INC.
For the period ended Dec 31, 2025. Filed Feb 13, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 13, 2026
BIO$386.48-0.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets at
Consolidated Balance Sheets
(In millions, except share data)
| December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $529.8 | $488.1 |
| Short-term investments | 1,010.9 | 1,176.4 |
| Accounts receivable, less allowance for credit losses of $5.5 and $9.2 as of December 31, 2025 and 2024, respectively | 460.6 | 452.5 |
| Inventory | 740.7 | 760.0 |
| Prepaid expenses | 136.5 | 122.6 |
| Other current assets | 27.7 | 30.7 |
| Total current assets | 2,906.2 | 3,030.3 |
| Property, plant and equipment, net | 539.9 | 528.1 |
| Operating lease right-of-use assets | 170.0 | 160.5 |
| Goodwill, net | 579.8 | 410.5 |
| Purchased intangibles, net | 174.3 | 293.6 |
| Other investments | 6,103.6 | 4,839.2 |
| Other assets | 102.7 | 101.9 |
| Total assets | $10,576.5 | $9,364.1 |
Consolidated Balance Sheets
(continued)
(In millions, except share data)
| December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $129.0 | $122.3 |
| Accrued payroll and employee benefits | 172.3 | 124.2 |
| Current maturities of long-term debt and notes payable | 1.3 | 1.2 |
| Income and other taxes payable | 36.6 | 31.2 |
| Current operating lease liabilities | 36.1 | 41.7 |
| Other current liabilities | 141.7 | 147.2 |
| Total current liabilities | 517.0 | 467.8 |
| Long-term debt, net of current maturities | 1,201.7 | 1,200.4 |
| Deferred income taxes | 1,059.4 | 818.0 |
| Operating lease liabilities | 145.7 | 131.4 |
| Other long-term liabilities | 199.1 | 177.2 |
| Total liabilities | 3,122.9 | 2,794.8 |
| Commitments and contingent liabilities | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.0001 par value, 7,500,000 shares authorized; issued and outstanding - none | — | — |
| Class A common stock, $0.0001 par value; 80,000,000 shares authorized; shares issued - 25,199,760 and 25,191,463 at 2025 and 2024, respectively; shares outstanding - 21,924,284 and 22,936,735 at 2025 and 2024, respectively | — | — |
| Class B common stock, $0.0001 par value; 20,000,000 shares authorized; shares issued and outstanding - 5,066,110 and 5,074,409 at 2025 and 2024, respectively | — | — |
| Additional paid-in capital | 476.0 | 463.2 |
| Class A treasury stock at cost, 3,275,476 shares at 2025 and 2,254,728 shares at 2024 | (1,009.6) | (772.1) |
| Retained earnings | 8,176.3 | 7,416.4 |
| Accumulated other comprehensive loss | (189.1) | (538.2) |
| Total stockholders’ equity | 7,453.6 | 6,569.3 |
| Total liabilities and stockholders’ equity | $10,576.5 | $9,364.1 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.